Compass Therapeutics, Inc. short interest in 2023
In 2023, Compass Therapeutics, Inc.'s disclosed short interest ran from 1.68% of shares outstanding on 15 Mar 2023 to 1.78% on 29 Dec 2023, a change of +0.10 percentage points. The year's high was 3.67% on 14 Jul 2023 and its low 1.57% on 31 Mar 2023, averaging 2.44% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 29.98 days on 31 Aug 2023. Full history: Compass Therapeutics, Inc..
Cite this page
By year: 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.68% (15 Mar 2023)
- End of year
- 1.78% (29 Dec 2023)
- Change
- +0.10 pp
- High
- 3.67% (14 Jul 2023)
- Low
- 1.57% (31 Mar 2023)
- Average
- 2.44%
- Highest days to cover
- 29.98 (31 Aug 2023)
- SEC filings marked
- 7
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Mar 2023 | 1.68% | 8.40 | 10-K filed |
| 31 Mar 2023 | 1.57% | 7.25 | |
| 14 Apr 2023 | 1.64% | 3.12 | |
| 28 Apr 2023 | 1.73% | 7.93 | |
| 15 May 2023 | 1.63% | 8.33 | 10-Q filed, results (8-K) |
| 31 May 2023 | 1.61% | 5.81 | |
| 15 Jun 2023 | 1.76% | 7.34 | |
| 30 Jun 2023 | 3.39% | 2.29 | |
| 14 Jul 2023 | 3.67% | 11.12 | |
| 31 Jul 2023 | 3.60% | 11.83 | |
| 15 Aug 2023 | 3.52% | 18.51 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 3.48% | 29.98 | |
| 15 Sep 2023 | 3.53% | 21.48 | |
| 29 Sep 2023 | 3.34% | 18.74 | |
| 13 Oct 2023 | 2.57% | 12.26 | |
| 31 Oct 2023 | 2.24% | 10.06 | |
| 15 Nov 2023 | 2.33% | 9.31 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 2.09% | 5.20 | |
| 15 Dec 2023 | 1.65% | 4.98 | |
| 29 Dec 2023 | 1.78% | 4.79 |
See also: Compass Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.